Australian cardiologists pour cold water on latest DOAC safety data

Fresh concerns have been raised about an increased risk of acute MI in patients who are taking dabigatran or rivaroxaban for atrial fibrillation, claim researchers involved in a large retrospective study that has revisited the issue. However, speaking to the limbic cardiologists say the findings most likely reflect the confounding nature of ‘real-world’ studies. Current ...

Already a member?

Login to keep reading.

© 2021 the limbic